Previous Article | Next Article 
Molecular and Cellular Biology, December 1999, p. 8335-8343, Vol. 19, No. 12
0270-7306/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Regulation of c-Fes Tyrosine Kinase and Biological
Activities by N-Terminal Coiled-Coil Oligomerization Domains
Haiyun
Cheng,1,2
Jim A.
Rogers,1
Nancy A.
Dunham,1 and
Thomas E.
Smithgall1,2,3,*
Eppley Institute for Research in
Cancer1 and Department of
Pharmacology,2 University of Nebraska Medical
Center, Omaha, Nebraska, and Department of Molecular Genetics
and Biochemistry, University of Pittsburgh School of Medicine,
Pittsburgh, Pennsylvania3
Received 9 July 1999/Accepted 19 August 1999
 |
ABSTRACT |
The cytoplasmic protein-tyrosine kinase Fes has been implicated in
cytokine signal transduction, hematopoiesis, and embryonic development.
Previous work from our laboratory has shown that active Fes exists as a
large oligomeric complex in vitro. However, when Fes is expressed in
mammalian cells, its kinase activity is tightly repressed. The Fes
unique N-terminal sequence has two regions with strong homology to
coiled-coil-forming domains often found in oligomeric proteins. Here we
show that disruption or deletion of the first coiled-coil domain
upregulates Fes tyrosine kinase and transforming activities in Rat-2
fibroblasts and enhances Fes differentiation-inducing activity in
myeloid leukemia cells. Conversely, expression of a Fes truncation
mutant consisting only of the unique N-terminal domain interfered with
Rat-2 fibroblast transformation by an activated Fes mutant, suggesting
that oligomerization is essential for Fes activation in vivo.
Coexpression with the Fes N-terminal region did not affect the
transforming activity of v-Src in Rat-2 cells, arguing against a
nonspecific suppressive effect. Taken together, these findings suggest
a model in which Fes activation may involve coiled-coil-mediated
interconversion of monomeric and oligomeric forms of the kinase.
Mutation of the first coiled-coil domain may activate Fes by disturbing
intramolecular coiled-coil interaction, allowing for oligomerization
via the second coiled-coil domain. Deletion of the second coiled-coil domain blocks fibroblast transformation by an activated form of c-Fes,
consistent with this model. These results provide the first evidence
for regulation of a nonreceptor protein-tyrosine kinase by coiled-coil domains.
 |
INTRODUCTION |
The c-fes proto-oncogene
is the normal cellular homolog of the transforming oncogenes found in
several avian and feline retroviruses (13, 15, 16, 19, 22,
38). The human c-fes locus encodes a cytoplasmic
protein-tyrosine kinase (Fes) primarily expressed in hematopoietic
cells of the myeloid lineage (7, 28, 40). Distinct from Src
and other nonreceptor tyrosine kinases, Fes has a long N-terminal
unique region, followed by a central SH2 domain and a C-terminal kinase
domain with a total molecular mass of 93 kDa. Previous studies have
shown that Fes is activated by numerous hematopoietic growth factors
(17, 18, 20, 30), implicating Fes as a downstream component
of cytokine receptor signaling. Other work has shown that Fes
suppresses the growth and induces the differentiation of the myeloid
leukemia cell line, K-562 (46). Taken together, these
results strongly suggest that Fes is involved in the regulation of
hematopoietic cell proliferation, differentiation and function.
Despite the important roles that Fes plays in hematopoietic
development, little is known about the mechanisms that regulate its
tyrosine kinase activity. In the absence of activating signals, Fes
tyrosine kinase activity is strongly repressed in cells
(12). Indeed, high-level overexpression of Fes is required
to induce kinase activation in vivo and to release transforming
activity in fibroblasts (8). Recent work from our laboratory
has shown that Fes autophosphorylation occurs by an intermolecular
mechanism, suggesting that oligomerization may be an important initial
event in Fes activation (36, 37). We also observed that
active Fes elutes from a gel filtration column as a large oligomer and
that the unique N-terminal domain is required for oligomerization. Taken together, these data suggest that oligomerization may be required
for kinase activation and that suppression of oligomerization may
represent a negative regulatory mechanism for Fes in vivo.
Computer analysis of the Fes N-terminal region revealed two strong
consensus sequences for the formation of coiled-coil oligomerization domains (36). Coiled-coil domains are comprised of
amphipathic
-helices with a characteristic heptad repeat in which
the first and fourth residues are hydrophobic and pack against each
other to form a hydrophobic core (26). The remainder of the
amino acids are often hydrophilic, helping to solvate the oligomeric structure. In this study, we investigated the contribution of the Fes
coiled-coil homology domains to the regulation of Fes tyrosine kinase
activity and biological function. We observed that disruption or
deletion of the more N-terminal coiled-coil domain (CC1) released Fes
tyrosine kinase activity in fibroblasts, leading to transformation. In
contrast to CC1, deletion of the second coiled-coil domain (CC2)
inhibited transformation by an activated form of Fes, suggesting that
CC2 may be required for oligomerization. In addition, a truncation
mutant of Fes bearing only the unique N-terminal domain strongly
suppressed the transforming and tyrosine kinase activity of an
activated Fes mutant in fibroblasts, providing further evidence that
Fes is active as an oligomer in living cells. These findings are
consistent with a mechanism of Fes kinase regulation that involves
interconversion of monomeric and oligomeric forms of the protein.
 |
MATERIALS AND METHODS |
Fes coiled-coil domain mutants.
The nucleotide sequence
encoding the first N-terminal coiled-coil homology domain of Fes (CC1;
amino acids 128 to 169) was deleted by using the Gene Editor
oligonucleotide-directed mutagenesis system according to the
manufacturer's instructions (Promega). A similar approach was utilized
to insert the
-turn motif Leu-Pro-Ala-Gly-Ser between N-terminal
amino acids 148 and 149, which form the boundary between the third and
fourth heptad repeats of the predicted coiled-coil structure. The
coding sequence for the second coiled-coil domain of Fes (CC2; amino
acids 310 to 344) was deleted by using a standard PCR-based strategy.
The N-terminal myristylation signal sequence of v-Src was added to the
N-terminal region of Fes and the coiled-coil domain mutants by using a
PCR-based approach. The 5' end of the Fes cDNA was amplified by using a
forward primer encoding a unique HindIII site and the
v-Src myristylation signal sequence Met-Gly-Ser-Ser-Lys-Ser-Lys fused
to Fes homologous sequences beginning with codon 3 and a reverse primer
that maps to the 5' end of the Fes unique N-terminal domain. The
resulting PCR product was digested with HindIII and AccI and swapped with the equivalent restriction fragment in
wild-type Fes or the coiled-coil domain mutants to generate the
full-length Myr-Fes cDNAs. The coding sequence for the Fes N-terminal
region (Fes-NT), the myristylated form of the N-terminal region
(Myr-Fes-NT), and related N-terminal constructs lacking the first or
second coiled-coil homology domains (
CC1-NT,
CC2-NT,
Myr-
CC1-NT, and Myr-
CC2-NT) were amplified by PCR from the
corresponding full-length Fes cDNAs. All Fes cDNAs used in these
studies bear a C-terminal FLAG epitope tag (37).
Expression of Fes proteins in 293T cells.
293T human
embryonic kidney cells (35) were maintained in Dulbecco
modified Eagle's medium (DMEM) supplemented with 5% fetal bovine
serum (FBS). Cells were transfected with Fes cDNAs in the expression
vector pCDNA3 (InVitrogen) by using a modified calcium phosphate method
described in detail elsewhere (37). Forty-eight hours later,
whole-cell protein extracts were prepared by heating equal numbers of
cells directly in sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) sample buffer. Proteins were resolved by
SDS-PAGE, transferred to polyvinylidene difluoride (PVDF) membranes, and probed with antibodies to FLAG (M2; Sigma) to detect Fes protein expression or with antiphosphotyrosine antibodies (PY20; Transduction Laboratories) to detect autophosphorylation.
Production of recombinant retroviruses and infection of Rat-2
fibroblasts.
Wild-type and coiled-coil mutant Fes cDNAs were
subcloned into the retroviral vector pSR
MSVtkneo (33).
Retroviruses were produced by cotransfecting 293T cells with the
pSR
-Fes constructs and an ecotropic packaging vector described
elsewhere (2, 24). The retroviral supernatant was collected
every 12 h for 3 days, and the supernatants were pooled and stored
at
80°C.
Rat-2 cells were maintained in DMEM supplemented with 5% FBS. For
viral infection, cells (2.5 × 105) were plated in
60-mm tissue culture dishes and incubated overnight at 37°C.
Retroviral supernatants (5 ml) were thawed on ice, supplemented with
Polybrene to 4 µg/ml, and added to the cells. After incubation for
4 h at room temperature, the viral supernatants were removed and
replaced with 4 ml of fresh medium. The infected cells were then
incubated for 48 h at 37°C prior to further analysis. Replicate plates of cells were lysed and analyzed for Fes protein expression as
described above for the 293T cells.
Transformation assays.
Rat-2 fibroblast transformation was
assessed by using a focus-forming assay. Retrovirally infected Rat-2
cells (2 × 104) were plated in 60-mm tissue culture
dishes in the presence of 800 µg of G418 per ml. The cells were
incubated at 37°C for 2 weeks, at which time they were Wright-Giemsa
stained and observed by light microscopy. For some experiments, stained
foci were enumerated from a scanned image by using colony-counting
software (Bio-Rad GS-710 Calibrated Imaging Densitometer and Quantity
One software).
For coexpression experiments, Rat-2 cells were first infected with
recombinant retroviruses carrying the various Fes N-terminal
constructs
or empty virus as a negative control as described above.
At 48 h
postinfection, the cells were split and reseeded in 6-well
plates at
2 × 10
5 cells/well. The following day, the cells were
reinfected with
retroviruses carrying activated forms of Fes or v-Src,
incubated
for 48 h, and replated at 2 × 10
4
cells/60-mm culture dish in the presence of G418. Foci were stained
and
counted 2 weeks later as described
above.
In vitro tyrosine kinase assay for Fes.
Populations of Rat-2
cells stably expressing wild-type and mutant forms of Fes were lysed in
Fes lysis buffer (50 mM Tris-HCl, pH 7.4; 50 mM NaCl; 1 mM EDTA; 1 mM
MgCl2; 0.1% Triton X-100) supplemented with 25 µg of
aprotinin per ml, 50 µg of leupeptin per ml, 1 mM
phenylmethylsulfonyl fluoride, 20 mM NaF, 1 mM
Na3VO4, and 50 µM
Na2MoO4. Fes proteins were immunoprecipitated
from clarified cell lysates with the M2 anti-FLAG monoclonal antibody
resin. The immunoprecipitates were washed with radioimmune
precipitation assay buffer (50 mM Tris-HCl, 150 mM NaCl, 1% Triton
X-100, 0.1% SDS, 1 mM EDTA, 1% sodium deoxycholate), followed by
kinase assay buffer (50 mM HEPES, pH 7.4; 10 mM MgCl2). The
final pellets were incubated with [
-32P]ATP (10 µCi;
Dupont-New England Nuclear) and 2 µg of a glutathione S-transferase (GST) fusion protein containing amino acids
162 to 413 of the human Bcr protein. Previous studies have shown that this protein is strongly phosphorylated by Fes in vitro
(23). After incubation for 15 min at 30°C, the reactions
were stopped by heating in SDS-PAGE sample buffer. Phosphorylated
proteins were resolved on SDS-polyacrylamide gels and visualized by
using storage phosphorimaging.
Chemical cross-linking.
Fes N-terminal domain constructs
were expressed as FLAG fusion proteins in 293T cells. Cells were lysed
by sonication in Fes lysis buffer, and clarified cell lysates were
incubated with the bifunctional cross-linking reagent disuccinimidyl
suberate (DSS) at a final concentration of 1.0 mM as described
previously (36). The reactions were incubated for 5 min at
room temperature and stopped by heating in SDS-PAGE sample buffer.
Cross-linked Fes proteins were visualized by immunoblotting with
anti-FLAG antibodies.
Hematopoietic differentiation assay.
The human
erythroleukemia cell line K-562 (25) was obtained from the
American Type Culture Collection and grown in RPMI 1640 medium
containing 10% FCS. K-562 cells were infected with recombinant Fes
retroviruses by using a coculture approach. Cultures of virus-producing
293T cells were initiated by cotransfection with retroviral and
packaging plasmids as described above. At 2 days posttransfection, 4 ml
of DMEM containing 5% FCS and 3 × 105 K-562 cells
were added to the 293T cultures along with 4 µg of polybrene per ml.
After incubation for 2 days at 37°C, the K-562 cells were removed
from the 293T cell culture by aspiration. Infected K-562 cells were
replated on new culture dishes and incubated for an additional 2 days
at 37°C, allowing residual 293T cells to readhere. The infected K-562
cells were reharvested, counted by trypan blue exclusion, and plated at
105 cells/60-mm tissue culture dish in 4 ml of RPMI
containing 10% FCS and 800 µg of G418 per ml. Four days later, cells
were fixed for 20 min in 1% paraformaldehyde and stored at 4°C in
phosphate-buffered saline (PBS) prior to staining and flow cytometry.
For single-cell analysis of Fes expression, 105 fixed cells
were permeabilized with 0.05% saponin in RPMI containing 5% FBS
(RPMI-FBS) for 20 min. Cells were resuspended in a minimal volume of
RPMI-FBS containing the M2 anti-FLAG monoclonal antibody (20 µg/ml)
for 1 h. The cells were washed twice with RPMI-FBS and then
incubated with a goat anti-mouse immunoglobulin G-fluorescein isothiocyanate (FITC) conjugate (20 µg/ml in RPMI-FBS; Molecular Probes) for 1 h. The cells were then washed three more times prior to fluorescence-activated cell sorter analysis. Analysis of CD13 and
CD33 expression was performed with direct FITC-conjugated antibodies
for these myeloid differentiation markers (Southern Biotechnology
Associates) (6). Staining was performed as described above
for the M2 antibody, except the saponin was omitted. A population of
K-562 cells cocultured with 293T cells producing a retrovirus carrying
only the neo selection marker served as a negative control in all experiments.
 |
RESULTS |
Disruption of the first Fes coiled-coil homology domain (CC1)
upregulates Fes kinase activity in vivo.
Previous analysis of the
Fes unique N-terminal region with the COILS algorithm (27)
revealed two regions of strong homology to coiled-coil oligomerization
domains (36). We have designated these regions CC1 and CC2,
and their relative positions within the Fes structure are illustrated
in Fig. 1. To investigate the contribution of CC1 to the regulation of Fes kinase activity, we
generated two CC1 domain mutants in which this region was either deleted entirely (
CC1) or disrupted by insertion of a
-turn (
CC1; see Fig. 1). The
-turn sequence chosen
(Leu-Pro-Ala-Gly-Ser) was previously used to disrupt the coiled-coil
oligomerization domain of the human breakpoint cluster region protein
(Bcr) (31). Initial characterization of these mutants was
conducted after transient expression in the human embryonic kidney cell
line, 293T. Whole-cell protein extracts were prepared and analyzed by immunoblotting to determine the expression level and extent of autophosphorylation. As shown in Fig. 2,
wild-type Fes was strongly expressed in these cells but displayed no
detectable autophosphorylation, a result consistent with the tight
negative regulation of Fes kinase activity observed previously in this
cell line and in other systems (12, 23). However, disruption
or deletion of the CC1 domain led to enhanced autophosphorylation of
Fes, a result which is indicative of kinase activation.

View larger version (27K):
[in this window]
[in a new window]
|
FIG. 1.
Fes constructs used in this study. The structure of
wild-type human c-Fes is shown at the top, which includes a unique
N-terminal region, an SH2 domain, and a C-terminal kinase domain. The
locations of the two regions with strong homology to coiled-coil
oligomerization domains are indicated as shaded boxes and labeled CC1
and CC2. The CC1 mutant with an insertion of the -turn sequence
Leu-Pro-Ala-Gly-Ser is also shown ( CC1), as well as the CC1 deletion
mutant ( CC1). Variants of all three proteins with the v-Src
myristylation signal added to the N terminus are designated Myr-Fes,
Myr- CC1, and Myr- CC1. Also shown is the structure of the Myr-Fes
CC2 deletion mutant (Myr- CC2).
|
|

View larger version (41K):
[in this window]
[in a new window]
|
FIG. 2.
Disruption or deletion of the first N-terminal
coiled-coil homology domain (CC1) stimulates Fes tyrosine
autophosphorylation in 293T cells. Wild-type Fes (Fes), Fes with an
N-terminal myristylation signal (Myr-Fes) and the corresponding CC1
mutants ( CC1, CC1, Myr- CC1, and Myr- CC1) were transiently
expressed in human 293T cells as described in Materials and Methods.
Whole-cell protein extracts were prepared in SDS-PAGE sample buffer,
and Fes expression (top) and autophosphorylation (bottom) were analyzed
by immunoblotting. Cells transfected with an empty expression vector
were included as a negative control (Control).
|
|
Similar experiments were also conducted with a form of Fes bearing the
v-Src myristylation signal sequence on its N terminus
(Myr-Fes)
(
11,
24). This modification targets Fes to membranes
and
releases its transforming activity (see below). As shown in
Fig.
2,
Myr-Fes exhibits a low level of autophosphorylation, indicating
that
targeting Fes to membranes partially releases its kinase
activity.
However, deletion or disruption of the CC1 domain significantly
enhanced Myr-Fes autophosphorylation in 293T cells (Fig.
2). This
result shows that the effect of CC1 disruption on kinase activity
is
independent of the subcellular localization of Fes and is consistent
with a negative regulatory function for the CC1 domain in the
regulation of Fes tyrosine kinase activity in
vivo.
Mutagenesis of the CC1 domain enhances Fes transforming and
tyrosine kinase activities in Rat-2 fibroblasts.
To determine the
effect of CC1 mutation on Fes biological activity, we introduced the
myristylated versions of the
CC1 and
CC1 Fes mutants into Rat-2
fibroblasts by using recombinant retroviruses. The infected cells were
plated and observed for the appearance of transformed foci 10 to 14 days after infection, and the results are shown in Fig.
3. Mutation or deletion of CC1 induced
the rapid appearance of many transformed foci relative to the Myr-Fes
control containing the wild-type CC1 domain (Fig. 3A). In the case of the
CC1 mutant, the number of foci observed by the end of the 14 day
incubation was more than 50-fold higher than that observed with Myr-Fes
under these culture conditions. In addition, foci formed by fibroblasts
expressing either of the CC1 mutations attained a much larger size
compared to Myr-Fes (Fig. 3B). Control fibroblasts expressing wild-type
Fes without the myristylation signal exhibited extremely low
focus-forming activity, a result consistent with previous results
demonstrating that Fes has tightly regulated tyrosine kinase and
transforming activities in Rat-2 cells (12).

View larger version (11K):
[in this window]
[in a new window]
|
FIG. 3.
Deletion or disruption of the first N-terminal
coiled-coil domain (CC1) enhances Myr-Fes transforming activity in
Rat-2 cells. Wild-type Fes, Fes with an N-terminal myristylation signal
(Myr-Fes), and Myr-Fes with insertion (Myr- CC1) or deletion
(Myr- CC1) mutations in the CC1 domain were introduced into Rat-2
fibroblasts by using recombinant retroviruses. Infected cells were
selected with G418 for 2 weeks and observed for the appearance of
transformed foci. (A) After Wright-Giemsa staining, foci from three
independent experiments were counted daily from day 10 to 14, and the
average of the results is shown (± the standard deviation [SD]). (B)
The average focus size was also determined for each culture under
low-power microscopy. Results shown are the average values for three
independent experiments ± the SD. Symbols: , c-Fes; ,
Myr-Fes; , Myr- CC1; , Myr- CC1.
|
|
We also investigated the transforming activity of the Fes constructs
bearing the same CC1 mutations but lacking the N-terminal
myristylation
signal sequence. However, we were unable to stably
express these
mutants in the Rat-2 cell background, thus preventing
analysis of their
transforming activity. Whether CC1 mutation
is sufficient for
transformation or whether a membrane-targeting
or other relocalization
signal is also required is not clear at
this
point.
The results shown in Fig.
3 demonstrate that CC1 mutation results in a
strong enhancement of Fes focus-forming activity. To
determine whether
this effect was due to an enhancement of tyrosine
kinase activity as
observed previously in the transient-transfection
system (Fig.
2), Fes
kinase activity was measured in an immune
complex kinase assay both in
terms of autophosphorylation and
substrate phosphorylation. Populations
of Rat-2 cells expressing
Fes, Myr-Fes, Myr-

CC1, and Myr-

CC1 were
lysed, and the Fes proteins
were recovered by immunoprecipitation.
After washing, the immunoprecipitates
were incubated with
[

-
32P]ATP and the substrate protein, GST-Bcr. This
recombinant GST
fusion protein contains human Bcr amino acids 162-413, which include
the major tyrosine phosphorylation sites for this Fes
substrate
(
23,
29). As shown in Fig.
4, both of the CC1 mutants exhibited
increased tyrosine kinase activity relative to the wild-type Fes
and
Myr-Fes controls. This result suggests that the increased
transforming
activity of the CC1 mutants is due to enhancement
of their intrinsic
tyrosine kinase activity and is consistent
with a role for the CC1
domain in the negative regulation of tyrosine
kinase activity in vivo.

View larger version (19K):
[in this window]
[in a new window]
|
FIG. 4.
Deletion or disruption of the first N-terminal
coiled-coil domain (CC1) enhances Myr-Fes tyrosine kinase activity in
Rat-2 cells. Fes, Myr-Fes, Myr- CC1, or Myr- CC1 proteins were
immunoprecipitated from lysates of Rat-2 fibroblasts and incubated in
vitro with [ -32P]ATP and a recombinant GST-Bcr fusion
protein substrate. Phosphorylated GST-Bcr, as well as
autophosphorylated Fes proteins, was resolved by SDS-PAGE, and the
relative levels of 32P incorporation were determined by
storage phosphorimaging. Equivalent levels of Fes proteins were present
in the immune complexes, as shown by immunoblot analysis (data not
shown). (A) Autophosphorylation. (B) Substrate phosphorylation. Results
shown are the average of two separate determinations. The entire
experiment was repeated three times with comparable results.
|
|
The CC1 domain is not required for oligomerization of the Fes
N-terminal region.
Previous work from our laboratory has shown
that the active form of Fes is oligomeric (36). Data shown
above indicate that deletion or mutation of the first coiled-coil
domain leads to kinase activation and fibroblast transformation. These
findings suggest that the Fes CC1 domain is not required for formation of the active oligomer and that CC2 or another portion of the N-terminal domain mediates oligomerization. To test this possibility directly, chemical cross-linking experiments were performed on Fes
N-terminal proteins with or without the CC1 deletion. The N-terminal
proteins were transiently expressed in 293T cells, and cell lysates
were incubated in the presence or absence of the bifunctional
cross-linking reagent, DSS. The reactions were analyzed for the
presence of cross-linked products by SDS-PAGE and immunoblotting, and
the result is shown in Fig. 5A. The
relative levels of the monomeric proteins and the major oligomeric
cross-linked products were determined by densitometry and are expressed
as a ratio in Fig. 5B. All of the N-terminal proteins tested yielded higher-molecular-weight products in the presence of the cross-linking reagent, including those bearing the N-terminal myristyl modification. Thus, the CC1 domain is not required for oligomerization of the N-terminal domain.

View larger version (42K):
[in this window]
[in a new window]
|
FIG. 5.
The CC1 domain is not required for cross-linking of Fes
N-terminal proteins. The N-terminal region of wild-type Fes (WT), the
myristylated form of the N-terminal region (Myr), the N-terminal region
lacking the first coiled-coil homology domain ( CC1), and the
myristylated version of the N-terminal CC1 deletion mutant (Myr- CC1)
were transiently expressed in 293T cells. Clarified cell extracts were
incubated in the presence (+) or absence ( ) of the bifunctional
cross-linking reagent DSS as described in Materials and Methods. (A)
Cross-linked products were visualized by immunoblotting. The locations
of the monomeric and oligomeric forms of the N-terminal proteins are
indicated. (B) The relative levels of the monomeric and major
oligomeric forms of the Fes N-terminal proteins were determined by
densitometry and then plotted as the ratio shown. Four independent
cross-linking experiments produced comparable results.
|
|
Transformation of Rat-2 fibroblasts by Myr-Fes is blocked by
coexpression with the N-terminal unique domain.
Recent studies
from our laboratory have shown that Fes autophosphorylation can be
suppressed by a kinase-inactive form of Fes in vitro, suggesting that
oligomerization may be an essential part of the activation mechanism in
vivo (36). To test this idea, we coexpressed a truncated
form of Fes consisting of only the myristylated N-terminal region
together with Myr-Fes in Rat-2 fibroblasts and scored the changes in
focus-forming activity after 2 weeks. As shown in Fig.
6, coexpression of Myr-Fes with the myristylated N-terminal domain led to a 75% reduction in the number of
transformed foci compared to control Rat-2 cells coinfected with
Myr-Fes and parental retroviruses. Immunoblots show equivalent expression of Myr-Fes in both cases, indicating that suppression of
transforming activity by the N-terminal domain is not due to differences in the expression of Myr-Fes.

View larger version (42K):
[in this window]
[in a new window]
|
FIG. 6.
Suppression of Myr-Fes transforming activity by
coexpression with Fes N-terminal domain proteins. Rat-2 fibroblasts
were infected with recombinant retroviruses carrying the wild-type Fes
N-terminal sequence (WT N-term), the N-terminal sequence lacking the
first coiled-coil homology domain ( CC1 N-term), or the N-terminal
sequence lacking the second coiled-coil homology domain ( CC2
N-term). A parallel series of N-terminal constructs bearing the v-Src
myristylation sequence was also tested (indicated as + Myr). Cells
infected with a retrovirus carrying only the neo selection
marker served as a negative control (Con). Forty-eight hours later, the
cells were reinfected with a Myr-Fes retrovirus and selected with G418
for 2 weeks as described in Materials and Methods. Foci were visualized
by Wright-Giemsa staining and counted by using a Bio-Rad Model GS-710
Scanning Densitometer and colony-counting software. Foci from three
independent cultures were counted and normalized to the negative
control average value; the bar graph shows the average normalized
value ± the SD. Expression of Myr-Fes and the N-terminal proteins
was verified by immunoblotting with the anti-FLAG antibody, which
recognizes the FLAG epitope fused to the C terminus of each protein
(lower two panels). This entire experiment was performed twice and
produced the same pattern of inhibition each time.
|
|
The activity of the wild-type Fes N-terminal region (without the
myristylation signal) was also tested in this suppression
assay. As
shown in Fig.
6, removal of the myristyl group reduced
the ability of
the N-terminal region to induce the suppression
of Myr-Fes transforming
activity. This difference suggests that
targeting of the N-terminal
domain to the same compartment as
Myr-Fes is important for suppression.
In addition, fusion to the
N-terminal myristylation signal may disturb
intramolecular interaction
between the CC1 and CC2 domains, promoting
the
trans-interaction
with Myr-Fes that is required for the
dominant-negative effect
(see
Discussion).
We also tested the suppressive activity of Fes N-terminal proteins with
deletions of either CC1 or CC2. Figure
6 shows that
both CC1 and CC2
N-terminal protein deletion mutants produced
approximately 50%
suppression of Myr-Fes focus-forming activity,
indicating that the
presence of either CC1 or CC2 is sufficient
for suppression. In this
case, suppression was independent of
the presence of the myristylation
signal sequence. These results
suggest that deletion of one coiled-coil
domain may free the remaining
coiled-coil to interact with Myr-Fes to
produce the dominant-inhibitory
effect.
We also used the suppression assay to determine the range of possible
coiled-coil interactions. For these experiments, transformation
was
induced by using the strongly transforming Myr-

CC1-Fes mutant,
which
has a single functional coiled-coil domain (CC2). As shown
in Fig.
7, the wild-type and myristylated forms
of the N-terminal
domain inhibited Myr-

CC1-Fes transforming activity
by approximately
30 and 75%, respectively, as observed for Myr-Fes
(Fig.
6). Interestingly,
the Fes N-terminal proteins lacking either the
CC1 or the CC2
domain also produced strong inhibitory effects. These
data suggest
that suppression of Myr-

CC1-Fes transforming activity
by

CC1
N-terminal proteins is mediated by CC2-CC2 interaction, while
suppression by

CC2 is mediated by CC1-CC2 interaction. Thus,
homomeric interactions between CC2 domains, as well as heteromeric
interactions between CC1 and CC2, appear to be possible. A very
similar
pattern of suppression was observed upon coexpression
of the same panel
of N-terminal proteins with the strongly transforming
Myr-

CC1 Fes
mutant as well (data not shown).

View larger version (36K):
[in this window]
[in a new window]
|
FIG. 7.
Suppression of Myr- CC1 Fes transforming activity by
coexpression with Fes N-terminal domain proteins. Rat-2 fibroblasts
were infected with recombinant retroviruses carrying the wild-type Fes
N-terminal sequence (N-term), the N-terminal sequence lacking the first
coiled-coil homology domain ( CC1 N-term), or the N-terminal sequence
lacking the second coiled-coil homology domain ( CC2 N-term). A
parallel series of N-terminal constructs bearing the v-Src
myristylation sequence was also tested (indicated as + Myr). Cells
infected with a retrovirus carrying only the neo selection marker
served as a negative control (Con). Forty-eight hours later, the cells
were reinfected with a Myr- CC1 Fes retrovirus and selected with G418
for 2 weeks as described in Materials and Methods. Foci were visualized
by Wright-Giemsa staining and counted by using a Bio-Rad Model GS-710
Scanning Densitometer and colony-counting software. Foci from three
independent cultures were counted and normalized to the negative
control average value; the bar graph shows the average normalized
value ± the SD. Expression of Myr- CC1 and the N-terminal
proteins was verified by immunoblotting with the anti-FLAG antibody,
which recognizes the FLAG epitope fused to the C terminus of each
protein (lower two panels). This entire experiment was performed twice
and produced the same pattern of inhibition each time.
|
|
To control for specificity in the N-terminal suppression studies, the
Fes N-terminal proteins used for the experiments shown
in Fig.
6 and
7
were also coexpressed with v-Src in the focus-forming
assay. v-Src
tyrosine kinase was chosen because it is dependent
upon myristylation
for fibroblast transformation (
21) but is
regulated by
mechanisms that do not involve coiled-coil domains.
As shown in Fig.
8, none of the c-Fes N-terminal proteins
affected
v-Src-induced transformation, supporting the conclusion that
the
suppressive actions of the N-terminal proteins are specific to
Fes-mediated transformation.

View larger version (38K):
[in this window]
[in a new window]
|
FIG. 8.
Coexpression with Fes N-terminal domain proteins does
not inhibit Rat-2 cell transformation by v-Src. Rat-2 fibroblasts were
infected with recombinant retroviruses carrying the wild-type Fes
N-terminal sequence (N-term), the N-terminal sequence lacking the first
coiled-coil homology domain ( CC1 N-term), or the N-terminal sequence
lacking the second coiled-coil homology domain ( CC2 N-term). A
parallel series of N-terminal constructs bearing the v-Src
myristylation sequence was also tested (indicated as + Myr). Cells
infected with a retrovirus carrying only the neo selection marker
served as a negative control (Con). Forty-eight hours later, the cells
were reinfected with a v-Src retrovirus and selected with G418 for 2 weeks as described in Materials and Methods. Foci were visualized by
Wright-Giemsa staining and counted by using a Bio-Rad Model GS-710
Imaging Densitometer and colony-counting software. Foci from three
independent cultures were counted and normalized to the negative
control average value; the bar graph shows the average normalized
value ± the SD. Expression of the N-terminal proteins was
verified by immunoblotting with the anti-FLAG antibody, which
recognizes the FLAG epitope fused to the C terminus of each protein
(lower panel). This entire experiment was performed twice and produced
the same result each time.
|
|
Data presented in Fig.
6 to
8 suggest that the ability of Fes
N-terminal proteins to suppress Myr-Fes-induced transforming
activity
involves direct interaction between the proteins, resulting
in the
formation of inactive mixed oligomers. To test this idea
further, we
performed kinase assays on Myr-Fes immunoprecipitates
from cultures
coexpressing the Myr-Fes N-terminal region or matched
controls. As
shown in Fig.
9, the extent of
autophosphorylation
of both Myr-Fes and the Myr-

CC1 Fes mutant were
inhibited by
more than 50% in the presence of the N-terminal protein.
These
results support direct inhibition of kinase activity in vivo as
a
mechanism for the suppressive action of the N-terminal region
and agree
with our previous results showing that a purified recombinant
N-terminal protein binds directly to Fes and inhibits its kinase
activity in vitro (
36).

View larger version (25K):
[in this window]
[in a new window]
|
FIG. 9.
Coexpression with the Fes N-terminal domain inhibits
autophosphorylation of Myr-Fes and the Myr-Fes CC1 domain deletion
mutant. Rat-2 fibroblasts expressing Myr-Fes, Myr- CC1, and
Myr- CC2 in the presence (+) or absence ( ) of the myristylated
N-terminal domain protein (N-term) were lysed, and the Fes proteins
were immunoprecipitated with the anti-FLAG antibody. The
immunoprecipitates were washed, incubated with
[ -32P]ATP, and separated by SDS-PAGE. The radiolabeled
proteins were transferred to PVDF membranes to allow determination of
protein levels by immunoblotting and densitometry. Incorporation of
32P into Fes proteins was determined by storage
phosphorimaging, and the resulting values were corrected for protein
levels and plotted as shown. This experiment was repeated three times
with comparable results.
|
|
The Fes CC2 domain is required for Fes transforming and kinase
activities.
Data presented so far point to the CC1 domain as a
negative regulator of Fes kinase activity that is not required for
oligomerization and activation and implicate the CC2 domain in oligomer
formation. To test this possibility directly, we created a CC2 deletion
in the context of Myr-Fes and compared its transforming activity with
wild-type Fes, Myr-Fes, and Myr-
CC1 Fes, as well as v-Src. As shown
in Fig. 10, deletion of the CC2 domain
completely inhibited the transforming activity of Myr-Fes. This result
is in sharp contrast to the effect of the CC1 mutation, which releases
strong transforming activity. Deletion of CC2 also resulted in greatly reduced kinase activity compared to Myr-Fes or Myr-
CC1 (Fig. 9).
These results show that CC2 is required for both biological and kinase
activities and suggest that it may contribute to oligomerization in
vivo.

View larger version (76K):
[in this window]
[in a new window]
|
FIG. 10.
Deletion of the second coiled-coil homology domain
inhibits the transforming activity of Myr-Fes. Rat-2 fibroblasts were
infected with recombinant retroviruses carrying wild-type c-Fes,
Myr-Fes, Myr- CC1, Myr- CC2, or v-Src. Cells infected with a
retrovirus carrying only the neo selection marker served as a negative
control (Con). Infected cells were cultured for 2 weeks in the presence
of G418 and were visualized by Wright-Giemsa staining. The experiment
was performed in triplicate; representative scanned images of the
stained foci are shown.
|
|
Fes CC1 domain mutants retain the ability to induce differentiation
in K-562 cells.
Previous studies have shown that expression of Fes
is sufficient to induce differentiation of the myeloid leukemia cell
line, K-562 (6, 46). However, studies of Fes-transfected
K-562 cell populations suggest that only a fraction of the cells
undergo differentiation after transfection with Fes (6).
This result suggests that a threshold of Fes tyrosine kinase activity
must be reached in order for differentiation to occur. Therefore, we tested the differentiation-inducing activity of the Fes mutants lacking
the CC1 domain which demonstrated elevated tyrosine kinase activity and
strong transforming potential in fibroblasts. Both the myristylated and
nonmyristylated forms of wild-type Fes and the
CC1 mutant were
tested. Each of these proteins was introduced into K-562 cells by using
recombinant retroviruses, and differentiation was assessed as the
percentage of cells that express the cell surface myeloid
differentiation antigens CD13 and CD33 as determined by flow cytometry.
The percentage of cells expressing Fes was also evaluated by this
method. As shown in Fig. 11, the ratio
of Fes protein to differentiation marker expression was approximately equal for wild-type Fes, Myr-Fes, and the CC1 deletion mutant without
the myristylation signal sequence. Interestingly, the myristylated form
of Fes with the CC1 deletion exhibited enhanced differentiation-inducing activity, as reflected by the higher ratio of
CD13 and CD33 to Fes protein expression. These results show that
deletion of the CC1 domain together with a membrane targeting signal
leads to robust differentiation signaling in K-562 cells and are
consistent with the fibroblast transformation data. Thus, CC1 also
appears to function as a negative regulator of Fes biological activity
in a physiologically relevant cellular context.

View larger version (37K):
[in this window]
[in a new window]
|
FIG. 11.
Differentiation of K-562 leukemia cells by Fes
coiled-coil domain mutants. K-562 myeloid leukemia cells were incubated
with 293T cells producing recombinant retroviruses carrying either
wild-type Fes, Myr-Fes, CC1, Myr- CC1, or only the G418 resistance
marker as a negative control (Con). After 48 h of coculture, K-562
cells were separated from the 293T cells and replated in the presence
of G418. Four days later, infected cells were analyzed by flow
cytometry for expression of Fes proteins by using the M2 anti-FLAG
monoclonal antibody and for cell surface CD13 and CD33 by using direct
FITC-conjugated antibodies to these myeloid cell-surface antigens. The
percentage of cells positive for Fes (open bars), CD13 (gray bars), and
CD33 (solid bars) are shown. Enhancement of differentiation by
Myr- CC1 was observed in two independent experiments.
|
|
 |
DISCUSSION |
Previous studies have established that Fes tyrosine kinase
activity is tightly regulated both in physiological sites of expression such as myeloid hematopoietic cells and after overexpression in rodent
fibroblasts and human embryonic kidney cells (12, 23, 28).
Efficient regulation of Fes kinase activity in these diverse cell types
implies that the mechanism of negative regulation may be intrinsic to
the structure of the kinase. Data presented in this report show that
the coiled-coil domains of Fes may have an important function in the
suppression of Fes tyrosine kinase activity in both the fibroblast
transformation model and in hematopoietic cells. Mutations in the more
N-terminal coiled-coil domain, including deletion, insertion of a
-turn, or even a single point mutation of a conserved leucine
residue (data not shown), all released Fes tyrosine kinase and
transforming activities in fibroblasts and enhanced
differentiation-inducing activity in K-562 cells. These data strongly
support an important negative regulatory function for this coiled-coil
motif and provide the first example of a coiled-coil domain
contributing to the negative regulation of a cellular tyrosine kinase.
Previous data from our laboratory have established that the active form
of Fes exists as a large oligomeric complex, at least in vitro
(36). In addition, we found that Fes autophosphorylation, which is a critical first step in the activation mechanism, occurs by a
trans mechanism reminiscent of growth factor receptor
tyrosine kinases (37). Similar results have been reported
for the Fes-related tyrosine kinase, v-Fps (42, 43). These
previous data suggested that oligomerization is the key to Fes
activation in vivo. Thus, suppression of Fes kinase activity may
require maintenance of the monomeric state as a mechanism to prevent
the trans phosphorylation required for kinase activation.
This may be achieved by intramolecular interaction between the first
and second coiled-coil domains. Evidence for CC1-CC2 interaction is
provided by in vivo suppression experiments in which Fes N-terminal
proteins lacking CC2 are shown to suppress transformation by Myr-
CC1
(Fig. 7); this Fes mutant lacks a functional CC1 domain. We have also
obtained additional evidence for CC1-CC2 interaction by using the yeast
two-hybrid system (data not shown). This model also explains why
mutations in the more N-terminal coiled-coil domain release tyrosine
kinase activity. Such mutations would prevent CC1-CC2 interaction and promote constitutive oligomerization. The formation of active Fes
oligomers appears to require CC2, since deletion of the CC2 domain
almost completely inhibited transformation by Myr-Fes and also greatly
reduced its kinase activity. Interestingly, mutations in the
CC2-homologous region of v-Fps have also been shown to reduce its
kinase and transforming activities (34). Determination of
the three-dimensional structure of the Fes N-terminal region will
provide an important test of this hypothetical model.
Data presented here also provide new evidence that oligomerization is
critical to Fes activation in living cells. The Fes N-terminal domain
serves as an effective dominant-negative mutant since it was able to
suppress Rat-2 cell transformation by Myr-Fes (Fig. 6). This result
suggests that the N-terminal domain of Fes is capable of interacting
with full-length Myr-Fes molecules, resulting in the formation of
nonproductive oligomers that are unable to undergo trans
phosphorylation. These results are consistent with earlier work from
our laboratory showing that both the Fes N-terminal domain and a
full-length kinase-inactive Fes mutant can suppress wild-type Fes
autophosphorylation in vitro (36). Importantly, both the
isolated N-terminal region and the kinase-dead Fes mutant can form
physical complexes with wild-type Fes in vitro (36).
Although our data are consistent with a model in which CC1 may regulate
Fes kinase activity via intramolecular interaction with CC2,
alternative hypotheses should be considered as well. For example, the
CC1 domain or other features of the Fes N-terminal region may interact
in trans with inhibitory proteins which suppress Fes
oligomerization and activation. A number of trans-inhibitory proteins have been proposed as regulators of c-Abl, another nonreceptor tyrosine kinase with tightly regulated tyrosine kinase and transforming activities (41). In the case of c-Abl, negative regulation
seems to require an intact SH3 domain, since mutations in this domain are strongly activating in vivo. Whether or not similar interacting proteins exist that suppress the tyrosine kinase activity of Fes will
require further investigation.
Although data presented here provide some of the first evidence
demonstrating regulation of a cellular tyrosine kinase by coiled-coil
domains in vivo, previous work has shown that coiled coils contribute
to the constitutive activation of the Bcr-Abl and TEL-Abl oncoproteins
associated with various leukemias (9, 31). In each case,
translocations result in the fusion of the c-Abl tyrosine kinase to a
coiled-coil oligomerization function provided by Bcr or TEL. In the
case of Bcr-Abl, N-terminal Bcr-encoded sequences form a
tetramerization motif that is required for constitutive activation of
the Abl kinase, as well as for localization to the actin cytoskeleton
(31). Interestingly, coexpression of a peptide containing
the Bcr oligomerization domain is sufficient to reverse the transformed
phenotype of Bcr-Abl-transformed myeloid leukemia cells
(14). These data suggest that suppression results from the
formation of nonfunctional mixed oligomers and are consistent with our
results demonstrating that coexpression with the Fes N-terminal region
blocks transformation by activated forms of full-length Fes.
Intramolecular interactions are emerging as a common theme in the
regulation of nonreceptor protein-tyrosine kinases. Perhaps the
best-studied example involves kinases of the Src family. The X-ray
crystal structures of c-Src (44, 45) and the closely related
kinase Hck (39) strongly suggest that negative regulation involves two intramolecular interactions. First, tyrosine
phosphorylation of the conserved tail tyrosine residue induces
intramolecular interaction with the SH2 domain, an interaction long
suspected because mutations in either of these regions induce kinase
activation (4). A second interaction revealed by the crystal
structure involves the SH3 domain and an intramolecular ligand formed
by the linker region connecting the SH2 and kinase domains. This intramolecular interaction is also critical for effective negative regulation of Src family kinases, since mutations in the SH3 domain or
the linker region also release the tyrosine kinase and transforming activities of c-Src and Hck (3, 5, 10). Activation of Src
family kinases can also result from interactions with other proteins
that bind to the SH2 or SH3 domain or both, presumably by displacement
of these intramolecular interactions (1, 2, 32). These
findings with Src-related kinases suggest that association of Fes with
other proteins may also lead to activation by disturbing intramolecular, negative-regulatory interactions. For example, previous
work from our laboratory has shown that Fes associates with and
phosphorylates Bcr, the normal breakpoint-cluster region protein
(23, 29). Fes-Bcr interaction is mediated, in part, by the
Fes N-terminal region (29). More recently, we observed that
coexpression with Bcr induces Fes autophosphorylation (23). Association of Fes with Bcr may disrupt CC1-CC2 interaction, leading to
kinase activation. Bcr is also an oligomeric protein (31), suggesting that it is capable of interacting with several molecules of
Fes simultaneously. Recruitment of multiple Fes molecules into close
proximity may contribute to activation via trans phosphorylation.
 |
ACKNOWLEDGMENT |
This work was supported by grant CA58667 from the National
Institutes of Health.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Molecular Genetics and Biochemistry, University of Pittsburgh School of
Medicine, E1240 Biomedical Science Tower, Pittsburgh, PA 15261. Phone:
(412) 648-9495. Fax: (412) 624-1401. E-mail:
tsmithga+{at}pitt.edu.
 |
REFERENCES |
| 1.
|
Alexandropoulos, K., and D. Baltimore.
1997.
Coordinate activation of c-Src by SH3 and SH2 binding sites on a novel, p130Cas-related protein, Sin.
Genes Dev.
10:1341-1355[Abstract/Free Full Text].
|
| 2.
|
Briggs, S. D.,
M. Sharkey,
M. Stevenson, and T. E. Smithgall.
1997.
SH3-mediated Hck tyrosine kinase activation and fibroblast transformation by the Nef protein of HIV-1.
J. Biol. Chem.
272:17899-17902[Abstract/Free Full Text].
|
| 3.
|
Briggs, S. D., and T. E. Smithgall.
1999.
SH2-kinase linker mutations release Hck tyrosine kinase and transforming activities in rat-2 fibroblasts.
J. Biol. Chem.
274:26579-26583[Abstract/Free Full Text].
|
| 4.
|
Brown, M. T., and J. A. Cooper.
1996.
Regulation, substrates, and functions of Src.
Biochim. Biophys. Acta
1287:121-149[Medline].
|
| 5.
|
Erpel, T.,
G. Superti-Furga, and S. A. Courtneidge.
1995.
Mutational analysis of the Src SH3 domain: the same residues of the ligand binding surface are important for intra- and intermolecular interactions.
EMBO J.
14:963-975[Medline].
|
| 6.
|
Fang, F.,
S. Ahmad,
J. Lei,
R. W. Klecker,
J. B. Trepel,
T. E. Smithgall, and R. I. Glazer.
1993.
The effect of mutation of tyrosine 713 in p93c-fes on its catalytic activity and ability to promote myeloid differentiation in K-562 cells.
Biochemistry
32:6995-7001[Medline].
|
| 7.
|
Feldman, R. A.,
J. L. Gabrilove,
J. P. Tam,
M. A. S. Moore, and H. Hanafusa.
1985.
Specific expression of the human cellular fps/fes-encoded protein NCP92 in normal and leukemic myeloid cells.
Proc. Natl. Acad. Sci. USA
82:2379-2383[Abstract/Free Full Text].
|
| 8.
|
Feldman, R. A.,
D. R. Lowy,
W. C. Vass, and T. J. Velu.
1989.
A highly efficient retroviral vector allows detection of the transforming activity of the human c-fps/fes proto-oncogene.
J. Virol.
63:5469-5474[Abstract/Free Full Text].
|
| 9.
|
Golub, T. R.,
A. Goga,
G. F. Barker,
D. E. H. Afar,
J. McLaughlin,
S. K. Bohlander,
J. D. Rowley,
O. N. Witte, and D. G. Gilliland.
1996.
Oligomerization of the ABL tyrosine kinase by the Ets protein TEL in human leukemia.
Mol. Cell. Biol.
16:4107-4116[Abstract].
|
| 10.
|
Gonfloni, S.,
J. C. Williams,
K. Hattula,
A. Weijland,
R. K. Wierenga, and G. Superti-Furga.
1997.
The role of the linker between the SH2 domain and catalytic domain in the regulation and function of Src.
EMBO J.
16:7261-7271[Medline].
|
| 11.
|
Greer, P.,
J. Haigh,
G. Mbamalu,
W. Khoo,
A. Bernstein, and T. Pawson.
1994.
The Fps/Fes protein-tyrosine kinase promotes angiogenesis in transgenic mice.
Mol. Cell. Biol.
14:6755-6763[Abstract/Free Full Text].
|
| 12.
|
Greer, P. A.,
K. Meckling-Hansen, and T. Pawson.
1988.
The human c-fps/fes gene product expressed ectopically in rat fibroblasts is nontransforming and has restrained protein-tyrosine kinase activity.
Mol. Cell. Biol.
8:578-587[Abstract/Free Full Text].
|
| 13.
|
Groffen, J.,
N. Heisterkamp,
M. Shibuya,
H. Hanafusa, and J. R. Stephenson.
1983.
Transforming genes of avian (v-fps) and mammalian (v-fes) retroviruses correspond to a common cellular locus.
Virology
125:480-486[Medline].
|
| 14.
|
Guo, X. Y.,
J. M. Cuillerot,
T. Wang,
Y. Wu,
R. Arlinghaus,
D. Claxton,
C. Bachier,
J. Greenberger,
I. Colombowala, and A. B. Deisseroth.
1998.
Peptide containing the BCR oligomerization domain (AA 1-160) reverses the transformed phenotype of p210bcr-abl positive 32D myeloid leukemia cells.
Oncogene
17:825-833[Medline].
|
| 15.
|
Hampe, A.,
I. Laprevotte,
F. Galibert,
L. A. Fedele, and C. J. Sherr.
1982.
Nucleotide sequences of feline retroviral oncogenes (v-fes) provide evidence for a family of tyrosine-specific protein kinase genes.
Cell
30:775-785[Medline].
|
| 16.
|
Hanafusa, T.,
L.-H. Wang,
S. M. Anderson,
R. E. Karess,
W. S. Hayward, and H. Hanafusa.
1980.
Characterization of the transforming gene of Fujinami sarcoma virus.
Proc. Natl. Acad. Sci. USA
77:3009-3013[Abstract/Free Full Text].
|
| 17.
|
Hanazono, Y.,
S. Chiba,
K. Sasaki,
H. Mano,
A. Miyajima,
K. Arai,
Y. Yazaki, and H. Hirai.
1993.
c-fps/fes protein-tyrosine kinase is implicated in a signaling pathway triggered by granulocyte-macrophage colony-stimulating factor and interleukin-3.
EMBO J.
12:1641-1646[Medline].
|
| 18.
|
Hanazono, Y.,
S. Chiba,
K. Sasaki,
H. Mano,
Y. Yazaki, and H. Hirai.
1993.
Erythropoietin induces tyrosine phosphorylation and kinase activity of the c-fps/fes proto-oncogene product in human erythropoietin-responsive cells.
Blood
81:3193-3196[Abstract/Free Full Text].
|
| 19.
|
Huang, C.-C.,
C. Hammond, and J. M. Bishop.
1984.
Nucleotide sequence of v-fps in the PRC II strain of avian sarcoma virus.
J. Virol.
50:125-131[Abstract/Free Full Text].
|
| 20.
|
Izuhara, K.,
R. A. Feldman,
P. Greer, and N. Harada.
1994.
Interaction of the c-fes proto-oncogene product with the interleukin-4 receptor.
J. Biol. Chem.
269:18623-18629[Abstract/Free Full Text].
|
| 21.
|
Kamps, M. P.,
J. E. Buss, and B. M. Sefton.
1986.
Rous sarcoma virus transforming protein lacking myristic acid phosphorylates known polypeptide substrates without inducing transformation.
Cell
45:105-112[Medline].
|
| 22.
|
Lee, W.-H.,
K. Bister,
A. Pawson,
T. Robins,
C. Moscovici, and P. H. Duesberg.
1980.
Fujinami sarcoma virus: an avian RNA tumor virus with a unique transforming gene.
Proc. Natl. Acad. Sci. USA
77:2018-2022[Abstract/Free Full Text].
|
| 23.
|
Li, J., and T. E. Smithgall.
1996.
Co-expression with Bcr induces activation of the Fes tyrosine kinase and phosphorylation of specific N-terminal Bcr tyrosine residues.
J. Biol. Chem.
271:32930-32936[Abstract/Free Full Text].
|
| 24.
|
Li, J., and T. E. Smithgall.
1998.
Fibroblast transformation by Fps/Fes tyrosine kinases requires Ras, Rac and Cdc42 and induces extracellular signal-regulated and c-Jun N-terminal kinase activation.
J. Biol. Chem.
273:13828-13834[Abstract/Free Full Text].
|
| 25.
|
Lozzio, B. B.,
C. B. Lozzio,
E. G. Bamberger, and A. S. Feliu.
1981.
A multipotential leukemia cell line (K-562) of human origin.
Proc. Soc. Exp. Biol. Med.
166:546-550[Medline].
|
| 26.
|
Lupas, A.
1996.
Prediction and analysis of coiled-coil structures.
Methods Enzymol.
266:513-525[Medline].
|
| 27.
|
Lupas, A.,
M. Van Dyke, and J. Stock.
1991.
Predicting coiled coils from protein sequences.
Science
252:1162-1164[Free Full Text].
|
| 28.
|
MacDonald, I.,
J. Levy, and T. Pawson.
1985.
Expression of the mammalian c-fes protein in hematopoietic cells and identification of a distinct fes-related protein.
Mol. Cell. Biol.
5:2543-2551[Abstract/Free Full Text].
|
| 29.
|
Maru, Y.,
K. L. Peters,
D. E. H. Afar,
M. Shibuya,
O. N. Witte, and T. E. Smithgall.
1995.
Tyrosine phosphorylation of BCR by FPS/FES protein-tyrosine kinases induces association of BCR with GRB-2/SOS.
Mol. Cell. Biol.
15:835-842[Abstract].
|
| 30.
|
Matsuda, T.,
T. Fukada,
M. Takahashi-Tezuka,
Y. Okuyama,
Y. Fujitani,
Y. Hanazono,
H. Hirai, and T. Hirano.
1995.
Activation of Fes tyrosine kinase by gp130, an interleukin-6 family cytokine signal transducer, and their association.
J. Biol. Chem.
270:11037-1109[Abstract/Free Full Text].
|
| 31.
|
McWhirter, J. R.,
D. L. Galasso, and J. Y. J. Wang.
1993.
A coiled-coil oligomerization domain of bcr is essential for the transforming function of bcr-abl oncoproteins.
Mol. Cell. Biol.
13:7587-7595[Abstract/Free Full Text].
|
| 32.
|
Moarefi, I.,
M. LaFevre-Bernt,
F. Sicheri,
M. Huse,
C.-H. Lee,
J. Kuriyan, and W. T. Miller.
1997.
Activation of the Src-family tyrosine kinase Hck by SH3 domain displacement.
Nature
385:650-653[Medline].
|
| 33.
|
Muller, A. J.,
J. C. Young,
A. M. Pendergast,
M. Pondel,
R. N. Landau,
D. R. Littman, and O. N. Witte.
1991.
BCR first exon sequences specifically activate the BCR/ABL tyrosine kinase oncogene of Philadelphia chromosome-positive human leukemias.
Mol. Cell. Biol.
11:1785-1792[Abstract/Free Full Text].
|
| 34.
|
Park, W.-Y., and J.-S. Seo.
1995.
Leucine zipper-like domain regulates the autophosphorylation and the transforming activity of P130gag-fps.
Biochem. Biophys. Res. Commun.
211:447-453[Medline].
|
| 35.
|
Pear, W. S.,
G. P. Nolan,
M. L. Scott, and D. Baltimore.
1993.
Production of high-titer helper-free retroviruses by transient transfection.
Proc. Natl. Acad. Sci. USA
90:8392-8396[Abstract/Free Full Text].
|
| 36.
|
Read, R. D.,
J. M. Lionberger, and T. E. Smithgall.
1997.
Oligomerization of the Fes tyrosine kinase: evidence for a coiled-coil domain in the unique N-terminal region.
J. Biol. Chem.
272:18498-18503[Abstract/Free Full Text].
|
| 37.
|
Rogers, J. A.,
R. D. Read,
J. Li,
K. L. Peters, and T. E. Smithgall.
1996.
Autophosphorylation of the Fes tyrosine kinase: evidence for an intermolecular mechanism involving two kinase domain tyrosine residues.
J. Biol. Chem.
271:17519-17525[Abstract/Free Full Text].
|
| 38.
|
Shibuya, M., and H. Hanafusa.
1982.
Nucleotide sequence of Fujinami sarcoma virus: evolutionary relationship of its transforming gene with transforming genes of other sarcoma viruses.
Cell
30:787-795[Medline].
|
| 39.
|
Sicheri, F.,
I. Moarefi, and J. Kuriyan.
1997.
Crystal structure of the Src family tyrosine kinase Hck.
Nature
385:602-609[Medline].
|
| 40.
|
Smithgall, T. E.,
G. Yu, and R. I. Glazer.
1988.
Identification of the differentiation-associated p93 tyrosine protein kinase of HL-60 leukemia cells as the product of the human c-fes locus and its expression in myelomonocytic cells.
J. Biol. Chem.
263:15050-15055[Abstract/Free Full Text].
|
| 41.
|
Van Etten, R. A.
1999.
Cycling, stressed-out and nervous: cellular functions of c-Abl.
Trends Cell Biol.
9:179-186.
[Medline] |
| 42.
|
Weinmaster, G.,
M. J. Zoller, and T. Pawson.
1986.
A lysine in the ATP-binding site of P130gag-fps is essential for protein-tyrosine kinase activity.
EMBO J.
5:69-76[Medline].
|
| 43.
|
Weinmaster, G.,
M. J. Zoller,
M. Smith,
E. Hinze, and T. Pawson.
1984.
Mutagenesis of Fujinami sarcoma virus: evidence that tyrosine phosphorylation of p130gag-fps modulates its biological activity.
Cell
37:559-568[Medline].
|
| 44.
|
Williams, J. C.,
A. Weijland,
S. Gonfloni,
A. Thompson,
S. A. Courtneidge,
G. Superti-Furga, and R. K. Wierenga.
1997.
The 2.35 Å crystal structure of the inactivated form of chicken Src: a dynamic molecule with multiple regulatory interactions.
J. Mol. Biol.
274:757-775[Medline].
|
| 45.
|
Xu, W.,
S. C. Harrison, and M. J. Eck.
1997.
Three-dimensional structure of the tyrosine kinase c-Src.
Nature
385:595-602[Medline].
|
| 46.
|
Yu, G.,
T. E. Smithgall, and R. I. Glazer.
1989.
K562 leukemia cells transfected with the human c-fes gene acquire the ability to undergo myeloid differentiation.
J. Biol. Chem.
264:10276-10281[Abstract/Free Full Text].
|
Molecular and Cellular Biology, December 1999, p. 8335-8343, Vol. 19, No. 12
0270-7306/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
McPherson, V. A., Everingham, S., Karisch, R., Smith, J. A., Udell, C. M., Zheng, J., Jia, Z., Craig, A. W. B.
(2009). Contributions of F-BAR and SH2 Domains of Fes Protein Tyrosine Kinase for Coupling to the Fc{varepsilon}RI Pathway in Mast Cells. Mol. Cell. Biol.
29: 389-401
[Abstract]
[Full Text]
-
Delfino, F. J., Stevenson, H., Smithgall, T. E.
(2006). A Growth-suppressive Function for the c-Fes Protein-Tyrosine Kinase in Colorectal Cancer. J. Biol. Chem.
281: 8829-8835
[Abstract]
[Full Text]
-
Kanda, S., Mochizuki, Y., Nakamura, T., Miyata, Y., Matsuyama, T., Kanetake, H.
(2005). Pigment epithelium-derived factor inhibits fibroblast-growth-factor-2-induced capillary morphogenesis of endothelial cells through Fyn. J. Cell Sci.
118: 961-970
[Abstract]
[Full Text]
-
Laurent, C. E., Delfino, F. J., Cheng, H. Y., Smithgall, T. E.
(2004). The Human c-Fes Tyrosine Kinase Binds Tubulin and Microtubules through Separate Domains and Promotes Microtubule Assembly. Mol. Cell. Biol.
24: 9351-9358
[Abstract]
[Full Text]
-
McCafferty, D.-M., Craig, A. W. B., Senis, Y. A., Greer, P. A.
(2002). Absence of Fer Protein-Tyrosine Kinase Exacerbates Leukocyte Recruitment in Response to Endotoxin. J. Immunol.
168: 4930-4935
[Abstract]
[Full Text]
-
Zirngibl, R. A., Senis, Y., Greer, P. A.
(2002). Enhanced Endotoxin Sensitivity in Fps/Fes-Null Mice with Minimal Defects in Hematopoietic Homeostasis. Mol. Cell. Biol.
22: 2472-2486
[Abstract]
[Full Text]
-
Cheng, H. Y., Schiavone, A. P., Smithgall, T. E.
(2001). A Point Mutation in the N-Terminal Coiled-Coil Domain Releases c-Fes Tyrosine Kinase Activity and Survival Signaling in Myeloid Leukemia Cells. Mol. Cell. Biol.
21: 6170-6180
[Abstract]
[Full Text]
-
Craig, A. W. B., Zirngibl, R., Williams, K., Cole, L.-A., Greer, P. A.
(2001). Mice Devoid of Fer Protein-Tyrosine Kinase Activity Are Viable and Fertile but Display Reduced Cortactin Phosphorylation. Mol. Cell. Biol.
21: 603-613
[Abstract]
[Full Text]
-
Rogers, J. A., Cheng, H. Y., Smithgall, T. E.
(2000). Src Homology 2 Domain Substitution Modulates the Kinase and Transforming Activities of the Fes Protein-Tyrosine Kinase. Cell Growth Differ.
11: 581-592
[Abstract]
[Full Text]
-
Kanda, S., Lerner, E. C., Tsuda, S., Shono, T., Kanetake, H., Smithgall, T. E.
(2000). The Nonreceptor Protein-tyrosine Kinase c-Fes Is Involved in Fibroblast Growth Factor-2-induced Chemotaxis of Murine Brain Capillary Endothelial Cells. J. Biol. Chem.
275: 10105-10111
[Abstract]
[Full Text]
-
Lionberger, J. M., Smithgall, T. E.
(2000). The c-Fes Protein-Tyrosine Kinase Suppresses Cytokine-independent Outgrowth of Myeloid Leukemia Cells Induced by Bcr-Abl. Cancer Res.
60: 1097-1103
[Abstract]
[Full Text]
-
Lionberger, J. M., Wilson, M. B., Smithgall, T. E.
(2000). Transformation of Myeloid Leukemia Cells to Cytokine Independence by Bcr-Abl Is Suppressed by Kinase-defective Hck. J. Biol. Chem.
275: 18581-18585
[Abstract]
[Full Text]